MX2024010296A - Agonistas del receptor de crf2 y su uso en terapia. - Google Patents

Agonistas del receptor de crf2 y su uso en terapia.

Info

Publication number
MX2024010296A
MX2024010296A MX2024010296A MX2024010296A MX2024010296A MX 2024010296 A MX2024010296 A MX 2024010296A MX 2024010296 A MX2024010296 A MX 2024010296A MX 2024010296 A MX2024010296 A MX 2024010296A MX 2024010296 A MX2024010296 A MX 2024010296A
Authority
MX
Mexico
Prior art keywords
therapy
receptor agonists
sarcopenia
crf2
obesity
Prior art date
Application number
MX2024010296A
Other languages
English (en)
Spanish (es)
Inventor
Philip Janiak
Elisabetta Bianchi
Alessia Santoprete
Daniela Roversi
Martina Tripepi
Marie- Laure OZOUX
Original Assignee
Corteria Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corteria Pharmaceuticals filed Critical Corteria Pharmaceuticals
Publication of MX2024010296A publication Critical patent/MX2024010296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
MX2024010296A 2022-02-23 2023-02-21 Agonistas del receptor de crf2 y su uso en terapia. MX2024010296A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy
PCT/EP2023/054317 WO2023161229A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
MX2024010296A true MX2024010296A (es) 2024-09-18

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010296A MX2024010296A (es) 2022-02-23 2023-02-21 Agonistas del receptor de crf2 y su uso en terapia.

Country Status (15)

Country Link
US (1) US20260001928A1 (https=)
EP (2) EP4234574A1 (https=)
JP (1) JP2025508820A (https=)
KR (1) KR20240153565A (https=)
CN (1) CN118843638A (https=)
AU (1) AU2023224327A1 (https=)
CA (1) CA3247142A1 (https=)
ES (1) ES3063881T3 (https=)
HR (1) HRP20260115T1 (https=)
IL (1) IL314055A (https=)
IS (1) IS050770A (https=)
MX (1) MX2024010296A (https=)
PL (1) PL4482578T3 (https=)
WO (1) WO2023161229A1 (https=)
ZA (1) ZA202406196B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104264A1 (en) * 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US20250243255A1 (en) * 2020-08-19 2025-07-31 Sanofi Crf2 receptor agonists and their use in therapy

Also Published As

Publication number Publication date
KR20240153565A (ko) 2024-10-23
IS050770A (is) 2024-10-15
CN118843638A (zh) 2024-10-25
ZA202406196B (en) 2025-03-26
EP4482578C0 (en) 2025-12-24
ES3063881T3 (en) 2026-04-21
EP4482578B1 (en) 2025-12-24
EP4482578A1 (en) 2025-01-01
IL314055A (en) 2024-09-01
HRP20260115T1 (hr) 2026-03-13
EP4234574A1 (en) 2023-08-30
JP2025508820A (ja) 2025-04-10
US20260001928A1 (en) 2026-01-01
WO2023161229A1 (en) 2023-08-31
AU2023224327A1 (en) 2024-08-29
PL4482578T3 (pl) 2026-03-16
CA3247142A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
MX2024010296A (es) Agonistas del receptor de crf2 y su uso en terapia.
MX2023002087A (es) Agonistas del receptor crf2 y su uso en terapia.
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
RU2551977C2 (ru) Пептидные агонисты glp-2
AU2017200346B2 (en) Antiviral drugs for treatment of Arenavirus infection
Head et al. Imidazoline receptors, novel agents and therapeutic potential
UY25980A1 (es) Polimorfos de telmisartan
Kumar et al. Catecholamine-induced cardiomyopathy: an endocrinologist’s perspective
MX2026003024A (es) Agonista multireceptor y uso medico del mismo
AR107890A1 (es) Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
ECSP21091203A (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
CO2025005958A2 (es) Agonistas del receptor del péptido-1 similar al glucagón
Del Duca et al. Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin
US20190062371A1 (en) Peptide compositions and related methods
AU2021201669A1 (en) Methods for treating hypotension
CO2023000307A2 (es) Polipéptidos de mybpc3 y usos de los mismos
MX2025005440A (es) Agonistas del receptor del peptido-1 similar al glucagon
CA3073011A1 (en) Acylated oxyntomodulin peptide analog
JP2020536121A5 (https=)
AU2017252015A1 (en) Peptide-oligourea foldamer compounds and methods of their use
TR201900959T4 (en) COMPOSITIONS AND ITS MEDICAL USE.
FI3648788T3 (fi) Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
PE20252747A1 (es) Compuestos y metodos para reducir la expresion de pln
US20080221203A1 (en) Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease
CO2020001314A2 (es) Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante